Latest News of MYE
Florida International Panthers and the CSU Bakersfield Roadrunners play in Fort Myers, Florida
By AP NEWS |
1 day ago
Receive AP Top 25 Poll Alerts in your inbox. Florida International Panthers (1-4) face CSU Bakersfield Roadrunners (3-2) at Alico Arena in Fort Myers. Florida International has 15.8 assists per game l...
Bristol Myers Squibb Clears Key Benchmark, Hitting 80-Plus RS Rating
By Investor's Business Daily |
4 days ago
Focus on stocks with an RS Rating of 80 or higher for your watchlist. Bristol Myers Squibb (BMY) now has an RS Rating of 83, indicating market leadership potential. Look for a proper buy point as the ...
Book Review: Chris Myers looks back on his career in 'That Deserves a Wow'
By AP NEWS |
5 days ago
Chris Myers, a veteran sports journalist, has had an illustrious career covering major events in various sports leagues. His memoir, "That Deserves a Wow," offers insights on achieving success in the ...
-
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
By Yahoo! Finance | 6 days agoBristol Myers Squibb shared promising data on CC-97540, a new CAR T Cell Therapy for autoimmune diseases, at ACR 2024. Manufactured using NEX-TTM process, it showed positive safety and efficacy result...
-
mRNA Shot Directly Linked To Transverse Myelitis
By The Washington Standard | 6 days agoThe article discusses the link between mRNA vaccines and transverse myelitis, highlighting the potential risks associated with these shots. It emphasizes the importance of addressing inflammation trig...
-
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug
By MarketWatch | 1 week agoBristol Myers Squibb received a positive recommendation from the EMA for expanded approval of its cancer drug Augtyro in Europe. The drug may soon be approved for treating specific types of lung cance...
-
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
By Yahoo! Finance | 1 week agoBristol Myers Squibb faces a $6.7 billion lawsuit for allegedly delaying drug approvals, cheating former Celgene shareholders. The lawsuit claims the delay cost shareholders an extra $9 per share in c...
-
Health Canada approves GSK's Ojjaara for myelofibrosis in anaemia patients
By Yahoo! Finance | 1 week agoHealth Canada has approved GlaxoSmithKline's Ojjaara (momelotinib) for treating myelofibrosis in adults with moderate-to-severe anaemia, based on positive results from Phase III trials....
-
Bristol Myers Squibb Gets RS Rating Upgrade
By Investor's Business Daily | 1 week agoBristol Myers Squibb's Relative Strength Rating increased from 63 to 79, but still falls short of the preferred score of 80 or higher. Top-performing stocks typically have an RS Rating above 80....
-
Bristol Myers's stock soars after AbbVie's schizophrenia-drug trial disappoints
By MarketWatch | 1 week agoBristol Myers Squibb's stock rose by 12.5% following AbbVie's announcement of disappointing trial results for their new schizophrenia drug, causing AbbVie's shares to drop by 12.4%....
-
AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.
By MarketWatch | 1 week agoAbbVie's stock dropped significantly as their schizophrenia drug, emraclidine, failed to show significant improvement in two Phase 2 trials. The drug did not meet the primary endpoint of demonstrating...
-
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?
By Yahoo! Finance | 2 weeks agoThe article discusses the current state of the pharmaceutical industry, highlighting the growth potential and challenges faced by companies like Bristol-Myers Squibb. It emphasizes the importance of b...
-
Texas police seeking person in Michael Myers mask spotted in area where man is fatally shot on Halloween
By NBC News | 3 weeks agoAuthorities are investigating the shooting death of Eric Pait in Harris County, Texas. The victim's estranged wife was also murdered in August. A suspect in a Michael Myers mask was spotted at the sce...
-
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
By CNBC | 3 weeks agoBristol Myers Squibb reported exceptional third-quarter earnings exceeding expectations, driven by Eliquis and growth portfolio drugs. The company raised revenue and earnings guidance for 2024 amidst ...
-
Bristol Myers Tops Earnings Views, Lifts Guidance
By Investor's Business Daily | 3 weeks agoBristol Myers Squibb (BMY) exceeded analyst expectations with Q3 earnings of $1.80/share on $11.89B in sales, driving the stock higher. The company projects an EPS of 75-95 cents and 5% revenue increa...